{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T03:22:58Z","timestamp":1761016978325},"reference-count":5,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,11]]},"DOI":"10.1097\/wnf.0b013e318271220b","type":"journal-article","created":{"date-parts":[[2012,11,14]],"date-time":"2012-11-14T09:13:46Z","timestamp":1352884426000},"page":"295","source":"Crossref","is-referenced-by-count":12,"title":["Eslicarbazepine Acetate in the Management of Refractory Bipolar Disorder"],"prefix":"10.1097","volume":"35","author":[{"given":"Kamal","family":"Nath","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arnab","family":"Bhattacharya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samir Kumar","family":"Praharaj","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-9-20210203","doi-asserted-by":"crossref","first-page":"2582","DOI":"10.1021\/jm980627g","article-title":". Anticonvulsant and sodium channel-blocking properties of novel 10,11-dihydro-5H-dibenzb,fazepine-5-carboxamide derivatives.","volume":"42","author":"Benes","year":"1999","journal-title":"J Med Chem"},{"key":"R2-9-20210203","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1111\/j.1528-1167.2007.00984.x","article-title":". Eslicarbazepine acetate: a double-blind, add-on, placebo controlled exploratory trial in adult patients with partial-onset seizures.","volume":"48","author":"Elger","year":"2007","journal-title":"Epilesia"},{"key":"R3-9-20210203","doi-asserted-by":"crossref","first-page":"71","DOI":"10.2165\/0023210-200923010-00005","article-title":"Eslicarbazepine acetate.","volume":"23","author":"McCormack","year":"2009","journal-title":"CNS Drugs"},{"key":"R4-9-20210203","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1111\/j.1528-1167.2012.03519.x","article-title":"Pharmacokinetics and drug interactions of eslicarbazepine acetate.","volume":"53","author":"Bialer","year":"2012","journal-title":"Epilepsia"},{"key":"R5-9-20210203","doi-asserted-by":"crossref","first-page":"723","DOI":"10.2147\/NDT.S5840","article-title":"Update on treatment of partial onset epilepsy: role of eslicarbazepine.","volume":"6","author":"Rauchenzauner","year":"2010","journal-title":"Neuropsychiatr Dis Treat"}],"container-title":["Clinical Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/WNF.0b013e318271220b","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T07:15:09Z","timestamp":1620976509000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00002826-201211000-00009"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,11]]},"references-count":5,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2012]]}},"URL":"https:\/\/doi.org\/10.1097\/wnf.0b013e318271220b","relation":{},"ISSN":["0362-5664"],"issn-type":[{"value":"0362-5664","type":"print"}],"subject":[],"published":{"date-parts":[[2012,11]]}}}